NIAC not recommending suspension of AstraZeneca jab despite blood clot fears

NIAC said the decision to suspend the use of the vaccine in some countries is based on "a small number of reports" of blood clotting events in people who received the AstraZeneca vaccine.

The National Immunisation Advisory Committee (NIAC) is not recommending the suspension of AstraZeneca over concerns around potential blood clots.

In a statement, NIAC said it is aware of recent reports that some EU member states have suspended the use of the AstraZeneca vaccine as a precautionary move, but said no change to NIAC’s recommendation on the use of the AstraZeneca vaccine is "currently warranted."